Unmasking Ketosis-Prone Diabetes in a Young Adult
Abstract
Ketosis-prone diabetes (KPD) is a unique clinical entity that does not fit the classic phenotypes of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM), although it can present similarly with severe hyperglycemia or diabetic ketoacidosis (DKA). This report describes a patient initially diagnosed with type 2 diabetes mellitus who was subsequently suspected to have ketosis-prone diabetes based on his clinical course. A 22-year-old man presented to the emergency department (ED) with hyperglycemia and was diagnosed with new-onset type 2 diabetes. He was closely monitored by his primary care physician (PCP) and outpatient pharmacist but continued to experience hyperglycemia. He was prescribed increasing doses of insulin, reaching up to 56 units of basal insulin nightly and 12 units of prandial insulin. Antibody testing was mildly elevated, although determined to be clinically insignificant. The patient utilized continuous glucose monitoring (CGM), and after several months of insulin therapy, he experienced hypoglycemic episodes. Consequently, he was titrated off all insulin therapy and successfully maintained euglycemia for eight months before experiencing disease relapse. Ketosis-prone diabetes is challenging to diagnose and remains under-recognized. The Aβ classification system differentiates patients based on the presence or absence of autoantibodies and the presence or absence of β-cell functional reserve. We suspect this patient's presentation is most…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.